InsidersTradesSigma
파미셀 Stock: price and directors' dealings · South Korea · DART (FSS)
Follow the 파미셀 stock price and the full management transaction log of the company, a listed issuer based in South Korea. Shares trade on KR KR, under the authority of DART (FSS). Operating in the Health Care sector, 파미셀 has recorded 49 public disclosures. Market capitalisation: €615.6bn. The latest transaction was reported on 10 July 2026 (Purchase). Among the most active insiders: 김현수. The full history is free.
49
Insider Decl.
n/a
Thresholds
n/a
34 ops.
Buy Volume
n/a
1 ops.
Sell Volume
17Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 10,058 of 28,124 companies
58.6
score / 100
Value55
Quality62
FCF yld5.0%
Earn yld6.0%
EV/EBITDA18.1x
ROE-29%
Gross mgn44%
Net mgn35%
Debt/EBITDA0.4x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 10 July 2026
Declarations49 total
25 of 49 declarations
About 파미셀
파미셀 is a healthcare and pharmaceutical company listed on the XKRX market. It specializes in the development of innovative pharmaceutical products.